Prevest Denpro Ltd Q3 FY2023 Concall Summary

Key Takeaways

• 27.9% 9M growth, margin dip by design: Revenue grew 27.89% YoY in 9M FY23 while EBITDA margin fell ~2 pp to 40.51%, driven by deliberate investment in R&D headcount, distribution, and exhibition-led marketing.
• US entry turns real with a \$1.7 mn anchor deal: A signed five-year supply agreement with a US sales company provides a concrete beachhead, and management says two more US deals are in advanced stages.
• New facility to double addressable capacity: The upcoming plant carries a ₹75 cr revenue capacity (expandable to ₹100 cr) and is expected to contribute ₹3–5 cr in its first year at just 10–15% utilization.
• Domestic market is a 1%-share greenfield: Management pegs its domestic share at ≤1% in a market dominated by MNCs and traders, and it grew 40% in 9M; the bet is that a slow dentist perception shift unlocks a long runway.
• What to watch next quarter: Whether the US pipeline converts into signed contracts with disclosed minimums, the pace of new-facility regulatory clearance, and whether Q4 revenue lands in the guided ₹10–12 cr band.

Growth Engine: Exports, US Entry & New Geographies

• US anchor deal de-risks entry: The \$1.7 mn, five-year agreement has started executing, with an advance payment already received for one order, giving the company a minimum revenue floor from a market it had not previously served.
• US pipeline building fast: Management is in advanced discussions with two additional US companies and is now signing only contracts with a minimum \$1 mn commitment, suggesting the initial deal was not a one-off.
• Geographic diversification cushions regional softness: New country entries in the first nine months included the Netherlands, Malaysia, Ireland, and France, which management explicitly frames as a hedge against slowdowns in any single region.
• Europe was soft in Q3: A depressive marketing scenario in Europe weighed on Q3 sales, yet overall business still grew ~7% QoQ because other regions compensated.
• Canada registration underway: Product registration has been initiated following US FDA clearance, with management hoping for some Canada business in FY24.
• Licensing delay shifted Q2 orders into Q3: Exports were held up after 20 September because medical device manufacturers needed a manufacturing license by 30 September; some of those orders rolled into Q3, flattering the quarter.

Atul Modi: "We are expecting to cross INR 50 crores in this financial year."

Margin Structure & Investment Cycle

• The margin dip is a hiring story: EBITDA margin fell to 40.51% from 42.86% YoY because the company added highly qualified personnel in R&D and more people in marketing to expand distribution lines.
• Other expenses rose on go-to-market push: Travel, tagging extension, and exhibition participation drove the increase, and management noted positive response from those exhibitions with good orders expected in coming years.
• Management insists margins are sustainable: The company is "very sure" margins will be maintained alongside positive growth, even while slowly adding people and increasing sales and marketing spend.
• Bottom-line profitability guided flat: The same ~40% profitability level seen in 9M is expected to hold for the full year FY23.
• Capital investment stayed large: ₹10.10 cr was deployed in capex, which management says keeps the company among industry leaders, and more capex is planned in coming quarters for marketing and research.

New Facility: Capacity, Timeline & Revenue Path

• Ready by year-end, revenue from FY24: The new facility will be completed by the end of FY23 but will only be put to use in FY24 after fulfilling regulatory compliances.
• Revenue ramp starts small: At 10–15% capacity utilization in year one, the facility is expected to generate ₹3–5 cr, with a path to 50% utilization in three to four years targeting ₹50 cr.
• Full capacity is ₹75 cr, expandable to ₹100 cr: The ₹75 cr base capacity can be enhanced with more value-added products, giving the company a long-term ceiling well above current revenue.

Domestic Market: The 1% Opportunity

• 40% domestic growth in 9M from a tiny base: Management attributes the growth to marketing strategy and effort, and expects domestic growth to accelerate further next year.
• Market share is ≤1%: The domestic dental consumables market is dominated by MNCs and trading companies, not real Indian manufacturers, leaving a large addressable pool.
• The perception barrier is the real constraint: Top dentists were trained on MNC products during their BDS and post-graduate years and default to brands like 3M and Dentsply; management likens it to preferring a Mercedes over a Tata car.
• Four-to-five-year horizon for mindshare: Management hopes that in the next four to five years, most top dentists will start using Prevest products, implying a slow, grinding adoption curve rather than a quick conversion.

Management: "It is basically a perception, which dentists have that the European brands are much better than the Indian brands. It is because of the products which they were trained on during their BDS or their post-graduation years, they get used to the product and it is very difficult to change the perception."

Product & Competitive Moat

• Top 20 products drive 80% of revenue: These are the most profitable SKUs; the remaining 80 products complement the range and matter for dentist relationships but are not significant in value.
• Pricing is the differentiator, quality is at par: Management claims quality matches international manufacturers, while the lower cost of production in Jammu and Kashmir provides a structural pricing advantage.
• Formulations are a 22-year barrier: The EBITDA margin attracts attention, but management argues the in-house formulations and streamlined production built over two decades are not easy for a newcomer to replicate quickly.
• One-stop-shop ambition: The company is expanding its product range so that a dentist can source all consumables from one manufacturer, which deepens the distributor relationship.
• 3D printing for dental applications: The R&D centre has developed and brought to market 3D printing products, which are expected to contribute significantly to top and bottom line in coming years.

Atul Modi: "There is no doubt it is very attractive at plus 40% EBITDA, but these are all formulations. These are in-house developments. Our efforts of the last 22 years, like we have streamlined our production. We have developed formulations. So it is not so easy for anyone else to come and eat the cake so easily, because it takes time to establish."

Guidance & Commitments

Key Metrics